OmniAb, Inc. OABI
Set alert
As of Nov 3, 10:13 AM ET
- YTD
- +178.92%
- 1 year
- +248.65%
- Open
- 5.12
- Prev close
- 5.09
- Mkt cap
- 749.72M
- Vol
- 290.89K
- Avg vol
- 1.74M
- EPS
- -0.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.10
- High
- 5.37
- Forward P/E
- -8.95
- Beta
- 0.44
- Short ratio
- 14.24
- Inst. own
- 68.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 4.00
- 200-d avg
- 4.38
- 1y target
- 9.63
News
2 days ago seekingalpha.com
OmniAb: A Self-Funding Option Book On 433 Partner Programs
OmniAb has reached self-sustaining cash flow, no longer requiring investor funding to operate, with 2026 projected as break-even for net cash usage. OABI's portfolio model offers contractually…
3 days ago benzinga.com
OmniAb Q3 2026 Earnings Call Transcript
OmniAb (NASDAQ:OABI) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
3 days ago seekingalpha.com
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com
OmniAb Q3 Earnings Call Highlights
OmniAb NASDAQ: OABI reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early…
4 days ago zacks.com
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
4 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
-
4 days ago benzinga.com
OmniAb Q3 EPS $(0.12), Inline, Sales $3.993M Beat $3.492M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period…
-
4 days ago benzinga.com
OmniAb Raises FY2026 Sales Guidance from $32.000M-$36.000M to $35.000M-$39.000M vs $35.036M Est
OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $32.000 million-$36.000 million to $35.000 million-$39.000 million vs $35.036 million estimate.
4 days ago businesswire.com
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics,…
-
3 weeks ago benzinga.com
Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12
Leerink Partners analyst Puneet Souda maintains OmniAb (NASDAQ:OABI) with a Outperform and raises the price target from $10 to $12.
-
3 weeks ago benzinga.com
StoneX Maintains Buy on OmniAb, Raises Price Target to $6
StoneX analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and raises the price target from $4 to $6.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
2 months ago benzinga.com
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
2 months ago benzinga.com
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
2 months ago benzinga.com
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
2 months ago benzinga.com
Why Is Omniab Stock Rallying After Eli Lilly Deal?
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
-
2 months ago benzinga.com
Market-Moving News for August 17th
HIVE: 9% | HIVE's BUZZ HPC Signs $350M Five-Year AI Cloud Deal With Investment-Grade Customer, Adding $70M ARR To Reach $180M Total Annualized Revenue OABI: 33% | OmniAb Announces Global…
2 months ago benzinga.com
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO,…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
-
2 months ago benzinga.com
OmniAb Raises FY2026 Sales Guidance from $28.000M-$33.000M to $32.000M-$36.000M vs $30.807M Est
OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $28.000 million-$33.000 million to $32.000 million-$36.000 million vs $30.807 million estimate.
-
2 months ago benzinga.com
OmniAb Q2 EPS $(0.05) Beats $(0.12) Estimate, Sales $13.415M Beat $4.693M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15) per…
-
3 months ago benzinga.com
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
8 months ago benzinga.com
OmniAb Q4 EPS $(0.11) Misses $(0.09) Estimate, Sales $8.376M Miss $9.003M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 23.6 percent. This is a 8.33 percent increase over losses of $(0.12) per…
8 months ago benzinga.com
A Look Ahead: OmniAb's Earnings Forecast
A Look Ahead: OmniAb's Earnings Forecast
-
11 months ago benzinga.com
OmniAb And Arrowmark Partners Sign A License And Services Agreement For Novel OmniAb-Derived Antibody Discovery Programs With Mabtrx Biosciences; OmniAb To Receive Revenue For Discovery Services As Well As Potential Equity And Royalties
OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx…
-
12 months ago benzinga.com
OmniAb Lowers FY2025 Sales Guidance from $20.000M-$25.000M to $18.000M-$22.000M vs $21.657M Est
OmniAb (NASDAQ:OABI) lowers FY2025 sales outlook from $20.000 million-$25.000 million to $18.000 million-$22.000 million vs $21.657 million estimate.
-
12 months ago benzinga.com
OmniAb Q3 EPS $(0.14), Inline, Sales $2.239M Miss $5.644M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.16) per share from the same period…
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
1 year ago benzinga.com
Top 3 Health Care Stocks You'll Regret Missing This Quarter
Top 3 Health Care Stocks You'll Regret Missing This Quarter
-
1 year ago benzinga.com
RBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $3
RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $4 to $3.
-
1 year ago benzinga.com
CORRECTION: OmniAb Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $3.897M Miss $5.334M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 4.46 percent. This is a 15.38 percent decrease over losses of $(0.13) per…
-
1 year ago benzinga.com
OmniAb Affirms FY2025 Sales Guidance of $20.000M-$25.000M vs $22.970M Est
OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 million-$25.000 million vs $22.970 million estimate.
-
1 year ago benzinga.com
Benchmark Reiterates Buy on OmniAb, Maintains $6 Price Target
Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $6 price target.
-
1 year ago benzinga.com
OmniAb Affirms FY2025 Sales Guidance of $20.00M-$25.00M vs $22.89M Est
OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.00 million-$25.00 million to $20.00 million-$25.00 million vs $22.89 million estimate.
-
1 year ago benzinga.com
OmniAb Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $4.15M Miss $4.49M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 10.53 percent increase over losses of $(0.19) per…
-
1 year ago benzinga.com
VERAXA Biotech Joins Forces with OmniAb to Develop Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate program addressing two attractive target molecules in cancer medicine. The Company will utilize…
-
1 year ago benzinga.com
RBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $4
RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $7 to $4.
-
1 year ago benzinga.com
Benchmark Maintains Buy on OmniAb, Lowers Price Target to $6
Benchmark analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and lowers the price target from $8 to $6.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
1 year ago benzinga.com
Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected
Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.